Full text is available at the source.
Adjunctive Dexmedetomidine Therapy in the Intensive Care Unit: A Retrospective Assessment of Impact on Sedative and Analgesic Requirements, Levels of Sedation and Analgesia, and Ventilatory and Hemodynamic Parameters
Dexmedetomidine added in intensive care: effects on sedation, pain relief, breathing, and heart function
AI simplified
Abstract
In a study involving 40 intensive care patients, 11 of 13 receiving propofol and 14 of 23 receiving lorazepam had their respective sedatives discontinued within 6 hours of starting adjunctive dexmedetomidine therapy.
- Adjunctive dexmedetomidine was associated with a reduction in the use of propofol but did not significantly alter the use of lorazepam or fentanyl.
- Adequate sedation levels decreased from 64.6% to 47.9% after the initiation of dexmedetomidine (p=0.001).
- The incidence of severe agitation increased from 4 patients before to 12 patients after starting dexmedetomidine (p=0.05).
- The number of patients experiencing severe pain rose from 1 before to 12 after dexmedetomidine was introduced (p=0.02).
- Nine patients experienced hypotension or bradycardia during the treatment period.
- Twenty-two patients were successfully extubated within 24 hours of starting dexmedetomidine.
AI simplified